Trial
NCT03871348
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sanofi
Collaborators
BioNTech RNA Pharmaceuticals GmbH
Condition
Metastatic Neoplasm
Intervention
SAR441000
Why stopped
Sponsor terminated the study for non-safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-10